12 March 2018
Former Chief Operating Officer of Kite Pharma, Cynthia M. Butitta, appointed to Autolus’ Board of Directors
London, 12 March 2018 – Autolus Limited, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, today announced the appointment of Cynthia M. Butitta to its board of directors, effective immediately.
Ms. Butitta is a highly experienced biopharma executive who most recently played an instrumental role in building Kite Pharma, Inc. from January 2014 until its acquisition by Gilead Sciences for approximately $11.9 billion in October 2017. She served as Kite’s Chief Financial Officer from January 2014 to May 2016 and as its Chief Operating Officer from March 2014 to September 2017. During her tenure, she helped secure over $1 billion in equity financing and shape the rapid growth of the company.
"We are delighted to welcome Cindy to our board of directors. Cindy is a highly accomplished leader in our industry and we look forward to drawing on her extensive experience as we enter the next phase of the company’s growth towards becoming a fully integrated company bringing advanced programmed T cell therapies to market.”
Dr. Christian ItinChairman and CEO of Autolus Limited
Ms. Butitta is a seasoned financial and operational executive with over 25 years of leadership experience in both biotechnology and high-technology industries. Prior to joining Kite, Ms. Butitta served as Senior Vice President and Chief Financial Officer of NextWave Pharmaceuticals, Inc., Chief Operating Officer and Chief Financial Officer of Telik Inc., and Vice President of Finance and Administration and Chief Financial Officer of Connetics, Inc. She received a B.S. degree in Business and Accounting from Edgewood College in Madison, Wisconsin, and an MBA in Finance from the University of Wisconsin─Madison.
“I am delighted to join the board of directors of Autolus at an exciting time in the company’s development. I look forward to leveraging my previous experience at Kite to help Autolus meet its goals of bringing transformative T cell therapies to the market and making a difference in the lives of patients.”
Cynthia M. ButittaNon-Executive Director of Autolus
Ms. Butitta also serves on the board of directors of Urogen Pharma Ltd. (NASDAQ:URGN).
– Ends –
+44 (0)7818 430877
Notes for Editors:
Autolus is a private, clinical-stage, biopharmaceutical company developing next-generation, differentiated, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and attack and kill these cells.
Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours. For further information, please visit the company’s website at: www.autolus.com